

Session VII: Addressing Barriers to Research Translation in AD/ADRD

Rema Raman, PhD
Professor of Neurology
Alzheimer's Therapeutic Research Institute
Keck School of Medicine of the University of Southern California

Current Research Support

NIA U24AG057437 (ACTC)

NIA U13AG067696 (IMPACT-AD)

NIA R25AG076392 (IMPACT-AD)

NIA R01AG054029 (A3)

NIA R01AG061848 (A45)

NIA R01AG068324 (ACTC LiBBY)

NIA R01AG065248 (ACTC START)

NNIA R33AG066543 (TRC-DS)

NIA U19AG024904 (ADNI)

NIA R56AG075744 (BEYONDD)

NIH U19AG078109 (HABS-HD)

NIH R01MH098062 (ADNI-D)

NIA R01AG056573/RF1AG056573

NIA RF1AG064584

NIA R01AG077578

Alzheimer's Association (IMPACT-AD, U.S. POINTER)

American Heart Association (ATRIL)

Gates Ventures (USC CTRL Program)

Critical areas of need and promise for AD/ADRD Clinical Trials

1. Focus on Internal and External validity

- Methodologically and operationally rigorous study designs
- Use community screening efforts
- Open data, image and sample sharing
- Evidence-based recruitment and retention strategies to enroll inclusive clinical trials

2. Develop the Next Generation Trials Workforce

- Training and education of clinical trials investigators and research teams

3. Invest in National and Global infrastructure and partnerships

- Increase clinical trials access by expanding national clinical trials networks to include two-way partnership between research and community hospitals/community centers
- Invest in developing site and study agnostic prescreening approaches
- Establish international clinical trial networks (including LMIC's) to conduct truly international trials with biologics and combinatorial therapies